Patients who had taken a previous cytoreductive therapy were divided into subgroups based on the treatment regimens used when Anagrelide Hydrochloride treatment was initiated, using the following variables:

•Withdrawal of previous cytoreductive therapy:

• Before: if a stop date of previous cytoreductive therapy was prior to the date of Anagrelide Hydrochloride initiation
• After: if a stop date of previous cytoreductive therapy was between the first administration and the last administration of Anagrelide Hydrochloride during the follow-up
• Not Withdrawn: in all other cases

Patients who had taken a previous cytoreductive therapy were divided into subgroups based on the treatment regimens used when Anagrelide Hydrochloride treatment was initiated, using the following variables:

•Withdrawal of previous cytoreductive therapy:

• Before: if a stop date of previous cytoreductive therapy was prior to the date of Anagreli
  
  

  Original Primary Outcome: To determine how different treatment regimens, during the initiation of XAGRID into a patient's essential thrombocythemia (ET) therapy, affect continuation with treatment in the first 6 months. [ Time Frame: 6 months ]
  
  

  Current Secondary Outcome:

  • Percentage of Subjects With Anagrelide Hydrochloride Starting Doses [ Time Frame: 6 months ]
  • Number of Subjects With Anagrelide Hydrochloride Titration Modifcations- First Modification Only [ Time Frame: 6 months ]
  • Summary of Adverse Drug Reactions (ADR): Withdrawal of Previous Cytoreductive Therapy Before Anagrelide Hydrochloride Initiation [ Time Frame: 6 months ]

    Patients who had taken a previous cytoreductive therapy were divided into subgroups based on the treatment regimens used when Anagrelide Hydrochloride treatment was initiated, using the following variables:

    •Withdrawal of previous cytoreductive therapy:

    • Before: if a stop date of previous cytoreductive therapy was prior to the date of Anagrelide Hydrochloride initiation
    • After: if a stop date of previous cytoreductive therapy was between the first administration and the last administration of Anagrelide Hydrochloride during the follow-up
    • Not Withdrawn: in all other cases
  • Summary of Adverse Drug Reactions: Withdrawal of Previous Cytoreductive Therapy After Anagrelide Hydrochloride Initiation [ Time Frame: 6 months ]

    Patients who had taken a previous cytoreductive therapy were divided into subgroups based on the treatment regimens used when Anagrelide Hydrochloride treatment was initiated, using the following variables:

    •Withdrawal of previous cytoreductive therapy:

    • Before: if a stop date of previous cytoreductive therapy was prior to the date of Anagrelide Hydrochloride initiation
    • After: if a stop date of previous cytoreductive therapy was between the first administration and the last administration of Anagrelide Hydrochloride during the follow-up
    • Not Withdrawn: in all other cases
  • Summary of Adverse Drug Reactions: No Withdrawal of Previous Cytoreductive Therapy [ Time Frame: 6 months ]

    Patients who had taken a previous cytoreductive therapy were divided into subgroups based on the treatment regimens used when Anagrelide Hydrochloride treatment was initiated, using the following variables:

    •Withdrawal of previous cytoreductive therapy:

    • Before: if a stop date of previous cytoreductive therapy was prior to the date of Anagrelide Hydrochloride initiation
    • After: if a stop date of previous cytoreductive therapy was between the first administration and the last administration of Anagrelide Hydrochloride during the follow-up
    • Not Withdrawn: in all other cases
  • Summary of Adverse Drug Reactions: When the Dosing Was Consistent With the Summary of Product Characteristics (SmPC) [ Time Frame: 6 months ]

    Patients who had taken a previous cytoreductive therapy were divided into subgroups based on the treatment regimens used when XAGRID treatment was initiated, using the following variables:

    • Initiation of XAGRID dosing consistent with the Summary of Product Characteristics (SmPC):

    • Consistent if:

      • The starting dose was <=1 mg/day, AND
      • Any increase in dose was no more than 0.5mg/day, AND
      • Any increase in dose was made at least 7 days after first initiation or at least 7 days after any previous modification (up or down), AND
      • The maximum dose did not exceed 10 mg/day at any stage.
    • Inconsistent: in all other cases
  • Summary of Adverse Drug Reactions: When the Dosing Was Inconsistent With the Summary of Product Characteristics (SmPC) [ Time Frame: 6 months ]

    Patients who had taken a previous cytoreductive therapy were divided into subgroups based on the treatment regimens used when XAGRID treatment was initiated, using the following variables:

    • Initiation of XAGRID dosing consistent with the Summary of Product Characteristics (SmPC):

    • Consistent if:

      • The starting dose was <=1 mg/day, AND
      • Any increase in dose was no more than 0.5mg/day, AND
      • Any increase in dose was made at least 7 days after first initiation or at least 7 da
        
        

        Original Secondary Outcome:
        
        Information By: Shire
        

        Dates:
        Date Received: August 26, 2010
        Date Started: September 2010
        Date Completion:
        Last Updated: February 14, 2014
        Last Verified: February 2014
        

    

    Join Millions

    Sign Up For One Of Our
    Newsletters

    Email

    Sign Up